DIAGNOSIS OF DELAYED DRUG ALLERGIC REACTIONS



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Mechanisms of delayed druginduced allergies (DDIA), individual features of the immune response to the drug, influence of various cofactors (concomitant pathology, viral infection, insolation, etc.) create difficulties in diagnostics of drug allergy (DA). Identification and elimination of a causative drug allows to prevent the development of severe allergic reactions. Verification of DA diagnosis during the survey allows to avoid the unreasonable lifelong ban on application of certain drug, which often leads to decreasing of treatment efficiency and increasing its cost. In vitro diagnostic tests are safe, but laborious and expensive. This article will provide the review of literature, reflecting a modern view on the diagnosis of DDIA.

Full Text

Restricted Access

About the authors

T S Romanova

NRC Institute of Immunology FMBA of Russia

Email: ts romanova@mail.ru
24, Kashirskoe Shosse, Moscow, 115478, Russia

T N Myasnikova

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

L V Khludova

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

V G Smirnov

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

T V Latysheva

NRC Institute of Immunology FMBA of Russia

24, Kashirskoe Shosse, Moscow, 115478, Russia

References

  1. Nigen S, Knowles SR, Shear NH. Drug eruptions: approaching the diagnosis of drug-induced skin diseases. J Drugs Dermatol. 2003; 2(3): 278-299.
  2. Mayorga C, Sanz ML, Gamboa P, Garcia-Aviles MC, Fernande J, Torres MJ, on behalf of the Spanish Society of Allergy and Clinical Immunology (SEAIC) Immunology and Drug Allergy Committee, In Vitro Methods for Diagnosing Non-immediate Hypersensitivity Reactions to Drugs. J Investig Allergol Clin Immunol. 2013; 23(4): 213-225.
  3. Thong BY, Mirakian R, Castells M, Pichler WJ, Romano A, Bonadonna P, Diana D, Kowalski M, Yanez A, Lleonart R, Sanchez-Borges M, Demoly P. A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. World Allergy Organ J. 2011; 4(12): 257-270. doi: 10.1097/W0X.0b013e31823dc02c.
  4. Nyfeler B, Pichler WJ. The lymphocyte transformation test in for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy. 1997; 27: 175-181. doi: 10.1111/j.1365-2222.1997.tb00690.x.
  5. Pichler WJ, Tilch J. The lymphocyte transformation test in for the diagnosis of drug hypersensitivity. Allergy. 2004; 59(8): 809-820. doi: 10.1111/j.1398-9995.2004.00547.x.
  6. Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, Koren G. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Mol Diagn Ther. 2009; 13(5): 313-30. doi: 10.1007/bf03256336.
  7. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007; 62(12): 1439-1444. doi: 10.1111/j.1398-9995.2007.01553.x.
  8. Schnyder B, Pichler WJ. Skin and laboratory tests in amoxicillin and penicillin-induced morbilliform skin eruption. Clin Exp Allergy. 2000; 30(4): 590-595. doi: 10.1046/j.1365-2222.2000.00787.x.
  9. Rodriguez-Pena R, Lopez S, Mayorga C, Antunez C, Fernandez TD, Torres MJ, Blanca M. Potential involvement of dendritic. cells in delayed-type hypersensitivity reactions to betalactams. J Allergy Clin Immunol. 2006; 118(4): 949-56. doi: 10.1016/j.jaci.2006.07.013.
  10. El-Ghaiesh S, Sanderson JP, Farrell J, Lavergne SN, Syn WK, Pirmohamed M, Park BK, Naisbitt DJ. Characterization of drug-specific lymphocyte responses in a patient with drug-induced liver injury. J Allergy Clin Immunol. 2011; 128(3): 680-683. doi: 10.1016/j.jaci.2011.04.031.
  11. Berger D, Pichler W, Savic S, Schoenenberger R, Borer H. Fever, pneumonia and eosinophilia. Praxis. 2007; 96(40): 1543-1547. doi: 10.1024/1661-8157.96.40.1543.
  12. Matsuno O, Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, Nureki S, Ando M, Miyazaki E, Kumamoto T. Drug induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med. 2007; 212(1): 49-53. doi: 10.1620/tjem.212.49.
  13. Ono E, Miyazaki E, Matsuno O, Nureki S, Okubo T, Ando M, Kumamoto T. Minocycline-Induced Acute Eosinophilic Pneumonia: Controversial Results of Lymphocyte Stimulation Test and Re-challenge Test. Intern Med. 2007; 46(9): 593-595. doi: 10.2169/internalmedicine.46.6235.
  14. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012; 13(1): 39. doi: 10.1186/1465-9921-13-39.
  15. Spanou Z, Keller M, Britschgi M, Yawalkar N, Fehr T, Neuweiler J, Gugger M, Mohaupt M, Pichler WJ. Involvement of drugspecific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol. 2006; 17(10): 2919-2927. doi: 10.1681/asn.2006050418.
  16. Beeler A, Pichler WJ. In vitro Tests of T-Cell-Mediated Drug Hypersensitivity. Drug Hypersensensivity. Basel, Karger. 2007: 380-390. doi: 10.1159/000104215.
  17. Beeler A, Zaccaria L, Kawabata T, Gerber BO, Pichler WJ. CD69 upregulation on T-cells as an in vitro marker for de-layed-type drug hypersensitivity. Allergy. 2008; 63(2): 181-188. doi: 10.1111/j.1398-9995.2007.01516.x.
  18. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell-mediated drug allergy. Clin Exp Allergy. 2011; 41(4): 461-470. doi: 10.1111/j.1365-2222.2011.03701.x.
  19. Halevy S, Cohen AD, Grossman N. Clinical implications of in vitro drug-induced interferon gamma release from peripheral blood lymhpocytes in cutaneous adverse drug reaction. J Am Acad Dermatol. 2005; 52(2): 254-261. doi: 10.1016/j.jaad.2004.05.006.
  20. Naisbitt DJ, Farrell J, Wong G, Depta JH, Dodd CC et al. Characterizations of drug-specific T-cell in lamotrigine hypersensitivity. J Allergy Clin Immunol. 2003; 111(6): 1393-1403. doi: 10.1067/mai.2003.1507.
  21. Hari Y, Urwyler A, Hurni M, Yawalkar N, Dahinden C et al. Distinkt serum cytokine levels in drug and measles-induced exantemа. Int Arch Allergy Immunol. 1999; 120(3): 225-229. doi: 10.1159/000024271.
  22. Pichler WJ, Zanni M, von Greyerz S, Schnyder B, Mau-ri-Hellweg D, Wendland T. High IL-5 production by human drug-specific T-cell clones. Int Arch Allergy Immunol. 1997; 113(1-3): 177-180. doi: 10.1159/000237539.
  23. Sachs B, Erdmann S, Al-Masauodi T, Merk HF. In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001; 144(2): 316-320. doi: 10.1046/j.1365-2133.2001.04021.x.
  24. Yawalkar N, Shrikhande M, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruphion. J Allergy Clin Immunol. 2000; 106(6): 1171-1176. doi: 10.1067/mai.2000.110922.
  25. Khalil G, EL-Sabban M., AL-Ghadban S et al. Cytokine expression profile of sensitized human T-lymphocytes following in vitro stimulation with amoxicillin. Eur Cytokin Netw. 2008; 19(3): 131-141.
  26. Lochmatter P, Beeler A, Kawabata TT, Gerber BO, Pichler WJ. Drug-specific in vitro relese of IL-2, IL-5, IL-13 and IFN-y in patients with delayed-type drug hypersensitivity. Allergy. 2009; 64(9): 1269-1278. doi: 10.1111/j.1398-9995.2009.01985.x.
  27. Britschgi M, Pichler WJ. Acute generalized exantematous pustulosis, a clue to neutrophil-mediated inflammatory processes orchestrated by T-cells. Curr Opin Allergy ClinImmunol. 2002; 2(4): 325-331. doi: 10.1097/00130832-20020800000006.
  28. Yawalkar N, Egli Y, Hari Y, Nievergelt H, Braathen LR, Pichler WJ. Infiltration of cytotoxic T-cells in drug-induced cutaneous eruptions. Clin Exp Allergy. 2000; 30(6): 847-855. doi: 10.1046/j.1365-2222.2000.00847.x.
  29. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P et al. Toхic epidermal necrolysis: effector cells are drug-specific cytotoxic T-cells. J Allergy Clin Immunol. 2004; 114(5): 1209-1215. doi: 10.1016/j.jaci.2004.07.047.
  30. Chung WH, Hung SI, Yang JY, Su SC, Huang SP et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Jonson syndrome and toхic epidermal necrolysis. Nat Med. 2008; 14(12): 1343-1350. doi: 10.1038/nm.1884.
  31. Schmid S, Kuechler PC, Britshgi M, Steiner UC, Yawalkar N et al. Acute generalized exantematous pustulosis: role of cytotoxic T-cells in pustule formation. Am J Pathol. 2002; 161(6): 2079-2086. doi: 10.1016/S0002-9440(10)64486-0.
  32. Hari Y, Frutig-Schnyder K, Hurni M, Yawalkar N, Zanny MP et al. T-cell involvement in cutaneous drug eruptions. Clin Exp Allergy. 2001; 31(9): 1398-1408. doi: 10.1046/j.1365-2222.2001.01164.x.
  33. Viard I, Wehrli P, Bullani R, Schneider P, Holler N et al. Inhibition of toxic epidermal necrolysis by blocade of CD95 with human intravenous immunoglobulin. Science. 1998; 282(5388): 490-493. doi: 10.1126/science.282.5388.490.
  34. Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell-mediated drug allergy. Clin Exp Alergy. 2011; 41(4): 461-470. doi: 10.1111/j.1365-2222.2011.03701.x.
  35. Zawodniak A, Lochmatter P, Yerly D, Kawabata T, Lerch M, Yawalkar N, Pichler WJ. In vitro detection of cytotoxic T- and NK-cells in peripheral blood of patients with various drug-induced skin diseases. Allergy. 2010; 65(3): 376-384. doi: 10.1111/j.1398-9995.2009.02180.x.
  36. Porebski G, Czarnobilska E, Bosak M. Cytotoxic-based assays in delayed drug hypersensitivity reactons induced by antiepileptic drugs. Pol Arch Med Wewn. 2015; 125(11)823-834. doi: 10.20452/pamw.3160.
  37. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002; (359): 727-732. doi: 10.1016/S0140-6736(02)07873-X.
  38. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet. Genomics. 2009; (19): 704-709. doi: 10.1097/fpc.0b013e328330a3b8.
  39. Hung SI, Chung WH, Liou LB, Chu СС, Lin M et al. HLA-B*5801 allele as genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005; 102(11): 4134-4139. doi: 10.1073/pnas.0409500102.
  40. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tochkin M et al. HLA-B locus in Japanese patients treated with anti-epileptic and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics J. 2008; 9(11): 1617-1622. doi: 10.2217/14622416.9.11.1617.
  41. Lonjou C, Thomas L, Borot N, Ledger N, Toma C et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J. 2006; 6(4): 265-268. doi: 10.1038/sj.tpj.6500356.
  42. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004; 428(6982): 486. doi: 10.1038/428486a.
  43. Man CB, Kwan P, Baum L, Yu E, Lau KM, Cheng AS, Ng MHL. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia. 2007; 48(5): 1015-1018. doi: 10.1111/j.1528-1167.2007.01022.x.
  44. Locharernkul C, Loplumlert J, Limotai C, Korkij W, Desudchit T Tongkobpetch S. Carbamazepin and phenytoin induced Stevens-Johnson syndrome is associated with the HLA-B*1502 allele in a Thai population. Epilepsia, 2008; (49): 2087-2091. doi: 10.1111/j.1528-1167.2008.01719.x.
  45. Metha TY, Prajapati LM, Mittal B, Joshi C, Sheth J et al. Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians. Indian J Dermatol Venereol Leprol. 2009; 75(6): 579-582. doi: 10.4103/0378-6323.57718.
  46. MCCormak M, Afirevic A, Bourgeois S, Farrell JJ, Deloukas P, Delanty N et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med. 2011; (64): 1134-1143. doi: 10.3410/f.9454964.10254054.
  47. Barbaud A, Reichert-Penetrat S, Trechot P, Jacquin-Petit, Ehlinger et al. The use of skin testing in the investigation of cutaneous adverse drug reactions. Br J Dermatol. 1998; 139(1): 49-58. doi: 10.1046/j.1365-2133.1998.02313.x.
  48. Bruynzeel DP, Maibach HI. Pach testing in systemic drug eruptions. Clin Dermatol. 1997; 15(4): 479-484. doi: 10.1016/s0738-081x(97)00007-2.
  49. Klein CE, Trautmann A, Zillikens D, Brocker EB. Patch testing in an unusual case of toxic epidermal necrolysis. Contact Dermatitis. 1996; 35(3): 175-176. doi: 10.1111/j.1600-0536.1996.tb02339.x.
  50. Machet L, Vaillant L, Dardaine V, Lorette G. Patch testing with clobazam: relapse of generalized drug eruption. Contact Dermatitis. 1992; 26(5): 347-348. doi: 10.1111/j.1600-0536.1992.tb00132.x.
  51. Demoly P, Adkinson NF, Brockow K, Castells M, Chiriac AM, Greenberger PA, Khan DA, Lang Dm, Park HS, Pichler W, Sanchez-Borges M, Shiohara N, Thong YH. International consensus on drug allergy. Allergy. 2014; 69(4): 420-437. doi: 10.1111/all.12350.
  52. Brockow K, Romano A, Blanca M, Ring J, Pichler W, Demoly P. General considerations for skin test procedures in the diagnosis of drug hypersensitivity. Allergy. 2002; 57(1): 45-51. doi: 10.1046/j.0105-4538.2001.00001.x-i8.
  53. Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A et al. European Society of Contact Dermatitis guideline for diagnostic patch testing-recommendations on best practice. Contact Dermatitis. 2015; 73(4): 195-221. doi: 10.1111/cod.12432.
  54. Harr T. Diagnostic approach to drug allergy. In: French L.E. Adverse Cutaneous Drug Eruptions. Basel, Karger. 2012; (97): 47-60. doi: 10.1159/000335615.
  55. Клиническая аллергология: Руководство для практических врачей. Под ред. Р.М. Хаитова. М.: Медпресс-информ, 2002: 623. [Clinical allergology: The management for practical doctors. Khaitov RM. Moscow: Medpress-inform, 2002: 623 (In Russ.)].
  56. Romano A, Viola M, Mondino C, Pettinato R, Di Fonso M, Papa G et al. Diagnosing nonimmediate reactions to pencillinis by in vivo tests. In Arch Allergy Immunol. 2002; 129(2): 169-174. doi: 10.1159/000065876.
  57. Lammintausta K, Kortekangas-Savolainen O. The usefulness of skin test to prove drug hypersensitivity. Br J Dermatol. 2005; 152(5): 968-974. doi: 10.1111/j.1365-2133.2005.06429.x.
  58. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS. 2002; 16(16): 2223-2225. doi: 10.1097/00002030-200211080-00017.
  59. Phadial A, Antunez C, Blanca-Lopez N, Fernandez TD, Cornejo-Garcia JA, Mayorga C et al. Non-immediate reactions to betalactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy. 2008; 38(5): 822-828. doi: 10.1111/j.1365-2222.2008.02961.x.
  60. Terrados S, Blanca M, Garcia J, Vega JM, Torres MJ et al. Non-immediate reactions to betalactams: prevalence and role ofthe different penicillins. Allergy. 1995; 50(7): 563-567. doi: 10.1111/j.1398-9995.1995.tb01200.x.
  61. Haan P, Bruynzeel DP, Van Ketel WG. Onset of penicillin rashes: relation between type of penicillin administered and type of immune reactivity. Allergy. 1986; 41(1): 75-78. doi: 10.1111/j.1398-9995.1986.tb00279.x.
  62. Romano A, Blanca M., Torres MJ, Bircher A, Aberer W et al. Diagnosis of nonimmediate reactions to beta-lactam antibiotics. Allergy. 2004; 59(11): 1153-1160. doi: 10.1111/j.1398-9995.2004.00678.x.
  63. Torres MJ, Sánchez-Sabaté E, Alvarez J, Mayorga C, Fernandez J, Padial A, Cornejo-Garcia JA, Bellôn T, Blanca M. Skin test evaluation in nonimmediate allergic reactions to penicillins. Allergy. 2004; 59(2): 219-224. doi: 10.1046/j.1398-9995.2003.00308.x.
  64. Vezir E, Dibek Misirliogu E, Civelek E, Capanoglu M, Gu-venir H et al. Direct oral provocation test in non-immediate mild cutaneous reactions related to beta-lactam antibiotics. Pediatric Allergy and Immunology. 2016; 27(1): 50-54. doi: 10.1111/pai.12493.
  65. Romano A, Quaratino D, Papa G, Di Fonso M, Venuti A. Aminopenicillin allergy. Arch Dis Child. 1997; 76(6): 513-517. doi: 10.1136/adc.76.6.513.
  66. Blanca-Lopez N, Zapatero L, Alonso E, Torres J, Fuentes V, Martinez-Molero I, Blanca M. Skin testing and drug provocation in nonimmediate reactions to aminopenicillins in children. Allergy. 2009; 64(2): 229-233. doi: 10.1111/j.1398-9995.2008.01903.x.
  67. Mendelson LM, Ressler C, Rosen JP, Selcow JE. Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization. J Allergy Clin Immunol. 1984; 73(1): 76-doi: 10.1016/0091-6749(84)90487-1.
  68. Moral L, Garde J, Toral T, Fuentes MJ, Marco N. Short protocol for the study of paediatric patients with suspected betalactam antibiotics hypersensitivity and low risk criteria. Allergol Immunopathol. 2011; 39(6): 337-341. DOI: doi. org/10.1016/j.aller.2010.10.002.
  69. Barbaud A., Goncalo M., Bruynzeel D. et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis. 2001; 45(6): 321-328. doi: 10.1034/j.1600-0536.2001.450601.x.
  70. Wolkenstein P, Chosidow O, Flechet ML, Bircher A. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996; 35(4): 234-236. DOI: 10.1111/ j.1600-0536.1996.tb02364.x.
  71. Macias E, Ruiz A, Moreno E, Laffond E, Davila I, Lo-rente F. Usefulness of interdermal test and patch test in the diagnosis of nonimmediate reactions to metamizol. Allergy. 2007; 62(12): 1462-1464. doi: 10.1111/j.1398-9995.2007.01487.x.
  72. Vernassiere C, Trechot P, Commun N, Schmutz JL, Barbaud A. Low negative predictive value of skin tests in investigating delayed reactions to radio-contrast media. Contact Dermatitis. 2004; 50(6): 359-366. doi: 10.1111/j.0105-1873.2004.00367.x.
  73. Brockow K, Romano A, Aberer W, Bircher AJ, Barbaud A et al. Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study. Allergy. 2009; 64(2): 234-241. doi: 10.1111/j.1398-9995.2008.01832.x.
  74. Лебедева НВ. Особенности диагностики и тактики ведения пациентов, перенесших реакции гиперчувствительности после введения йодсодержащих рентгеноконтрастных средств. Диссертация на соискание ученой степени кандидата мед. наук. М., 2013, 142 с. [Lebedeva N.V. Features of diagnostics and tactics of maintaining the patients who transferred reactions of a hypersensitivity after introduction of iodinated contrast tools. Dissertation for the degree of Candidate of Medical Sciences. M., 2013; 142 (In Russ.)].
  75. Aberer W, Birchera A, Romano A, Blanca M, Campi P et al. Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy. 2003; 58(9): 854-863. doi: 10.1034/j.1398-9995.2003.00279.x.
  76. Gleckman RA, Borrego F. Adverse reactions to antibiotics. Postgrad Med. 1997; 101(4): 97-108. DOI: 0.3810/pgm.1997.04.198.
  77. Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by accoustic rhinometry. Thorax. 2000; 55(11): 921-924. doi: 10.1136/thorax.55.11.921.
  78. Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J. 2000; 15(5): 863-869. doi: 10.1034/j.1399-3003.2000.15e09.x.
  79. Hannuksela M, Salu H. The repeated open application test (ROAT). Contact Dermatitis. 1986; 14(4): 221-227. doi: 10.1111/j.1600-0536.1986.tb01229.x.
  80. Lopez Serrano MC, Caballero MT, Barranco P, Martinez-Alzamora F. Booster responses in the study of allergic reactions to beta-lactam antibiotics. J Invest Allergol Clin Immunol. 1996; 6(1): 30-35.
  81. Romano A, Gaeta F, Valluzzi RL, Caruso C, Alonzi C, Viola M et al. Diagnosing nonimmediate reactions to cephalosporins. J Allergy Clin Immunol. 2012; 129(4): 1166-1169. doi: 10.1016/j.jaci.2011.12.995.
  82. Kauppinen K, Stubb S. Fixed eruptions - causative drugs and challenge tests. Br J Dermatol. 1985; 112(5): 575-578. doi: 10.1111/j.1365-2133.1985.tb15266.x.
  83. Blanca M, Fernandez J, Miranda A, Terrados S, Torres MJ et al. Cross-reactivity between penicillins and cephalosporins; clinical and immunologic studies. J Allergy Clin Immunol. 1989; 83(2): 381-385. doi: 10.1016/0091-6749(89)90122-x.
  84. Romano A, Di Fonso M, Papa G, Pietrantonio F, Federico F et al. Evaluation of adverse cutaneous reactions to aminopen-icillins with emphasis on those manifested by maculopapular rashes. Allergy. 1995; 50(2): 113-118. doi: 10.1111/j.1398-9995.1995.tb05066.x.
  85. Torres MJ, Mayorga C, Leyva L, Guzman AE, Cornejo-Garcia JA, Juarez C, Blanca M. Controlled administration of penicillin to patients with a positive history but negative skin and specific serum IgE tests. Clin Exp Allergy. 2002; 32(2): 270-276. doi: 10.1046/j.1365-2222.2002.01296.x.
  86. Romano A, Quaratino D, Di Fonso M, Papa G, Venuti A, Gasbarrini G. A diagnostic protocol for evaluationg nonimme-diate reactions to aminopenicillins. J Allergy Clin Immunol. 1999; 103(6): 1186-1190. doi: 10.1016/s0091-6749(99)70197-1.
  87. Hein UR, Chantraine-Hess S, Worm M, Zuberbier T, Henz BM. Evaluation of systemic provocation tests in patients with suspected allergic and pseudoallergic drug reactions. Acta Derm Venereol. 1999; 79(2): 139-142. doi: 10.1080/000155599750011372.
  88. Ring L, Galosi A, Przybilla B. Reverse placebo provocation in the diagnosis of anaphylactoid reactions to local anesthetics. J Allergy Clin Immunol. 1986; 77: 225. doi: 10.1016/0030-4220(93)90427-6.
  89. Moneret-Vautrin DA, Gueant JL, Kamel L, Laxenaire MC, El Kholty S, Nicolas JP. Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases. J Allergy Clin Immunol. 1988; 82(5): 745-752.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2017



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies